2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸ : 2019-05-29±³À°ÀÏÀÚ : 2019-05-29
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ¼¿ï ÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : À¯ÀüºÐÀÚÁø´ÜÇÐȸ
´ã´çÀÚ : À̼Ҷó
¿¬¶ôó : 02-795-9914
À̸ÞÀÏ :
kscp1@kams.or.kr ±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 17 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í Á¤È¸¿ø-8¸¸¿ø, Àü°øÀÇ-8¸¸¿ø, Àü¹®ÀÇ-12¸¸¿ø,»ê¾÷°è 15¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 08:30~09:00 2019 À¯ÀüÀÚ°Ë»ç±â°ü ÁúÆò°¡ ü°è ¹× ½É»ç ÀϹݻçÇ× ÀÌ¿µ°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:00~09:30 Àü»ê ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ ÇöÀå ½Ç»ç À¯Á¾ÇÏ(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:30~09:50 ½É»çÁ¡°ËÇ¥ ¼³¸í – °Ë»ç½Ç ¿î¿µ ¾ÈÁ¤¿(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:50~10:10 ½É»çÁ¡°ËÇ¥ ¼³¸í – ºÐÀÚÀ¯Àü ÀåÀÚÇö(³ì½ÊÀÚÀÇ·áÀç´Ü)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 10:10~10:30 ½É»çÁ¡°ËÇ¥ ¼³¸í – ¼¼Æ÷À¯Àü ÀÌÁø°æ(Çѱ¹¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 09:00~09:30 Screening risk individuals in health check up Ȳ±Ý·Ï(¼¿ïÀÇ°úÇבּ¸¼Ò)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 09:30~10:00 Personal identification and chimerism assay by NGS ±èÁöÀº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 10:00~10:30 NGS-based HLA typing ¹ÚÀ±Èñ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 09:00~09:30 Culture & slide preparation ¼ÕÁ¤¿Á(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-29 ±Ý°È¦A 09:30~10:00 Reading & interpretation ¼³Ã¢¾È(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 10:00~10:30 Point issues in past proficiency test ±è°æÈñ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 11:00~12:00 Molecular drivers of inherited hematopoietic malignancies Mark D. Ewalt(University of Colorado School of Medicine)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 12:00~13:10 Effectively manage your transplant patients with standardized & clinically validated results ÁöÇö¼÷(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 12:00~12:30 Clinical genetic testing using NGS: Lessons learned and future direction äÁ¾Èñ(¼¿ïÀÇ´ë Èñ±ÍÁúȯ¼¾ÅÍ)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 12:30~13:10 High throughput data analysis using dragen system Tan, Yue Ying(Sr Bioinformatics Specialist, Illumina)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 13:10~13:40 Low level somatic mosaicism in neurologic disorders °ÈÆö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 13:40~14:10 The scope of hereditary tumor syndrome is expanding in the NGS era ÀÌ¿ìâ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 14:10~14:40 Precision genomics and treatment in neuromuscular disorders ÀÌÁ¤È¯(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 13:10~13:40 ±¹³» À¯Àü»ó´ãŬ¸®´Ð ÇöȲ À¯Á¾ÇÏ(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 05-29 ±Ý°È¦A 13:40~14:10 À¯Àü »ó´ã Ŭ¸®´Ð ½ÃÀÛÇϱ⠱赵ÈÆ(°è¸íÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 14:10~14:40 À¯Àü »ó´ã Ŭ¸®´Ð ¿î¿µ A, B, C ½Å°æÈ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 13:10~13:40 Data analysis of DNA-Seq ±è¼±¿µ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 13:40~14:10 Data analysis of RNA-Seq ÀÌÁØÇü(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 14:10~14:40 Deep learning for genomics ¼º¹®¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 15:10~15:40 Epilepsy-related disorders ÀÓº´Âù(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 15:40~16:10 NGS-guided precision medicine in inherited eye disorders ÇÑÁø¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 16:10~16:40 Immune deficiency ±è¿¹Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 15:10~15:40 Urea cycle disorders and hyperammonemia ÀÌ°æÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-29 ±Ý°È¦A 15:40~16:10 Disorders of carnitine cycle and fatty acid oxidation disorders ±è¼¼¸²(³ì½ÊÀÚÀÇ·áÀç´Ü)
±³À°½Ã°£ 05-29 ±Ý°È¦A 16:10~16:40 Galactosemia ¾È¼±Çö(¼¿ïÀÇ°úÇבּ¸¼Ò)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 15:10~15:40 À¯ÀüÀÚÀç¹è¿ÀÇ Á¤¼ºÀû °ËÃâ ¼ÀÚ¿µ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 15:40~16:10 À¯ÀüÀÚÀç¹è¿ÀÇ Á¤·®Àû °ËÃâ Á¶¿µ¿í(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 16:10~16:40 ¿°±â¼¿ºÐ¼®À» ÀÌ¿ëÇÑ µ¹¿¬º¯ÀÌ °ËÃâ ±è¹Ì¿µ(ÇѸ²ÀÇ´ë)